To fast respond the coronavirus disease of 2019 (COVID-19) pandemic, the Indonesiangovernment has launched "Vaksinasi Gotong Royong" (a mutual cooperation vaccinationprogram) in which any company/legal entity/business entity may purchase vaccines to begiven free of charge to their employees and families of employees (The IndonesianMinistry of Health, 2021). Vaccines provided for this program include the severe acuterespiratory syndrome coronavirus 2 (SARS-CoV-2) inactivated vaccines produced bySinopharm.The Indonesian National Agency of Drug and Food Control (NADFC) has issued an EmergencyUse Authorization (EUA) for several COVID-19 vaccines, including the SARS-CoV-2 vaccine(Vero cell) inactivated produced by Sinopharm (NADFC, 2021). Following EUA, Kimia FarmaIndonesia as the holder of EUA has the obligation to monitor the safety and effectivenessin Indonesian population.
Not Provided
Biological: SARS-CoV-2 vaccine (Vero cell) inactivated
Two doses of 0.5 mL intramuscular injection containing 4 mcg (6.5 Unit) antigens with an
interval of 21-28 days in accordance with "Vaksinasi Gotong Royong" (mutual cooperation
vaccination program)
Inclusion Criteria:
Male or female subjects aged 18 years old and above; Will receive the SARS-CoV-2 vaccine
(Vero cell) inactivated produced by Sinopharm; Obtain informed consent to participate
this study
Exclusion Criteria:
Previous SARS-CoV-2 vaccination, except for drop out after the first vaccine dose of more
than 6 months ago; History of SARS-CoV-2 infection within the last 3 months
Laboratorium Klinik Kimia Farma Diponegoro Bandung
Bandung, Indonesia
Laboratorium Klinik Kimia Farma Cikini
Jakarta, Indonesia
Laboratorium Klinik Kimia Farma Medan
Medan, Indonesia
Laboratorium Klinik Kimia Farma Sutomo Semarang
Semarang, Indonesia
Not Provided